DNA vaccination for prostate cancer, from preclinical to clinical trials where-we stand?

Hdl Handle:
http://hdl.handle.net/10147/253652
Title:
DNA vaccination for prostate cancer, from preclinical to clinical trials where-we stand?
Authors:
Ahmad, Sarfraz; Sweeney, Paul; Sullivan, Gerald C; Tangney, Mark
Citation:
Genetic Vaccines and Therapy. 2012 Oct 09;10(1):9
Issue Date:
9-Oct-2012
URI:
http://dx.doi.org/10.1186/1479-0556-10-9; http://hdl.handle.net/10147/253652
Abstract:
Abstract Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms, strong clinical evidence is still lacking. This article provides an overview of the basic principles of DNA vaccines and aims to provide a summary of preclinical and clinical trials outlining the benefits of this immunotherapy in the management of PCa.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorAhmad, Sarfraz-
dc.contributor.authorSweeney, Paul-
dc.contributor.authorSullivan, Gerald C-
dc.contributor.authorTangney, Mark-
dc.date.accessioned2012-11-28T12:06:41Z-
dc.date.available2012-11-28T12:06:41Z-
dc.date.issued2012-10-09-
dc.identifier.citationGenetic Vaccines and Therapy. 2012 Oct 09;10(1):9-
dc.identifier.urihttp://dx.doi.org/10.1186/1479-0556-10-9-
dc.identifier.urihttp://hdl.handle.net/10147/253652-
dc.description.abstractAbstract Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms, strong clinical evidence is still lacking. This article provides an overview of the basic principles of DNA vaccines and aims to provide a summary of preclinical and clinical trials outlining the benefits of this immunotherapy in the management of PCa.-
dc.titleDNA vaccination for prostate cancer, from preclinical to clinical trials where-we stand?-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderSarfraz Ahmad et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2012-11-19T20:00:23Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.